Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine

Journal of Medical Virology

Volumn 84, Issue 2, 2012, Pages 336-344

  Ainai, Akira ^a   Tamura, Shin Ichi ^a   Suzuki, Tadaki ^a   Ito, Ryo ^a,b   Asanuma, Hideki ^a   Tanimoto, Takeshi ^c   Gomi, Yasuyuki ^c   Manabe, Sadao ^c   Ishikawa, Toyokazu ^c   Okuno, Yoshinobu ^c   Odagiri, Takato ^a   Tashiro, Masato ^a   Sata, Tetsutaro ^a   Kurata, Takeshi ^a   Hasegawa, Hideki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Influenza; Neutralizing antibody; Vaccine

Indexed keywords

HEMAGGLUTININ; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASSAY; CLINICAL ARTICLE; GEL FILTRATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; MALE; NORMAL HUMAN; NOSE MUCUS; SERUM; VIRUS NEUTRALIZATION;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASAL LAVAGE FLUID; VACCINATION; YOUNG ADULT;

EID: 83655180837     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22273     Document Type: Article

References (36)

1. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, Iwakura Y, Suzuki Y, Aizawa C, Sata T, Kurata T, Tamura S. 2002. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168:2930-2938.
2. Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura S, Kurata T, Sata T. 2004. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 74:328-335.
3. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB. 2007. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25:5367-5373.
4. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, Wolff M. 2000. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181:1133-1137.
5. Brandtzag P, Krajci P, Lamm ME, Kaetzl CS. 1994. Epitherial and hepatobiliary transort of polymeric immunogloburins. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGee JR, Bienenstock J, editors. Handbook of mucosal immunology. San Diego: Academic Press, pp 113-126.
6. Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett CD Jr, Lease GO. 1964. Comparisons of serologic and febrile responses in humans to vaccination with influenza a viruses or their hemagglutinins. J Lab Clin Med 63:5-13.
7. Durrer P, Gluck U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Gluck R. 2003. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21:4328-4334.
8. Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z. 2002. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20:1232-1239.
9. Hashigucci K, Ogawa H, Ishidate T, Yamashita R, Kamiya H, Watanabe K, Hattori N, Sato T, Suzuki Y, Nagamine T, Aizawa C, Tamura S, Kurata T, Oya A. 1996. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14:113-119.
10. Hierholzer JC, Suggs MT, Hall EC. 1969. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl Microbiol 18:824-833.
11. Ito R, Ozaki YA, Yoshikawa T, Hasegawa H, Sato Y, Suzuki Y, Inoue R, Morishima T, Kondo N, Sata T, Kurata T, Tamura S. 2003. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21:2362-2371.
12. Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S. 2000. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 18:2779-2788.
13. Kuno-Sakai H, Kimura M, Ohta K, Shimojima R, Oh Y, Fukumi H. 1994. Developments in mucosal influenza virus vaccines. Vaccine 12:1303-1310.
14. Kurono Y, Mogi G. 1987. Secretory IgA and serum type IgA in nasal secretion and antibody activity against the M protein. Ann Otol Rhinol Laryngol 96:419-424.
15. Lu BL, Webster RG, Hinshaw VS. 1982. Failure to detect hemagglutination-inhibiting antibodies with intact avian influenza virions. Infect Immun 38:530-535.
16. Murphy BR. 1994. Mucosal Immunity to Viruses. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGee JR, Bienenstock J, editors. Handbook of mucosal immunology. San Diego: Academic Press. pp 333-343.
17. Murphy BR, Clements ML. 1989. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 146:107-116.
18. Murphy BR, Webster RG. 1996. Orthomyxoviruses. In: Fields BN, Knipe DM, M HP, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, editors Fields virology. 3rd edition. Philadelphia: Lippincott Williams & Wilkins. pp 1397-1445.
19. Muszkat M, Yehuda AB, Schein MH, Friedlander Y, Naveh P, Greenbaum E, Schlesinger M, Levy R, Zakay-Rones Z, Friedman G. 2000. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol 61:100-106.
20. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S. 1990. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 28:1308-1313.
21. Palladino G, Mozdzanowska K, Washko G, Gerhard W. 1995. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69:2075-2081.
22. Ramphal R, Cogliano RC, Shands JW Jr, Small PA Jr. 1979. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun 25:992-997.
23. Renegar KB, Jackson GD, Mestecky J. 1998. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J Immunol 160:1219-1223.
24. Renegar KB, Small PA Jr, Boykins LG, Wright PF. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978-1986.
25. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37:937-943.
26. Song W, Vaerman JP, Mostov KE. 1995. Dimeric and tetrameric IgA are transcytosed equally by the polymeric Ig receptor. J Immunol 155:715-721.
27. Tamura S, Funato H, Hirabayashi Y, Kikuta K, Suzuki Y, Nagamine T, Aizawa C, Nakagawa M, Kurata T. 1990. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine 8:479-485.
28. Tamura S, Funato H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T. 1991. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 21:1337-1344.
29. Tamura S, Hasegawa H, Kurata T. 2010. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis 63:8-15.
30. Tamura S, Kurata H, Funato H, Nagamine T, Aizawa C, Kurata T. 1989. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit. Vaccine 7:314-320.
31. Tamura S, Kurata T. 2004. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57:236-247.
32. Tamura S, Tanimoto T, Kurata T. 2005. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 58:195-207.
33. Tamura SI, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A. 1992. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 22:477-481.
34. Taylor HP, Dimmock NJ. 1985. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 161:198-209.
35. Tobita K, Sugiura A, Enomote C, Furuyama M. 1975. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol 162:9-14.
36. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L. 2006. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24:254-262.